A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background: The most common cause of polyneuropathy is diabetes mellitus. Neuropathic pain is seen in 26% of diabetic population. Therapeutic techniques for this disease can become challenging. Method: This study was a prospective comparative double-blind randomized study which was conducted during an eight-week period. Totally, 104 painful diabetic peripheral polyneuropathy (PDPP) patients who had a minimum Visual Analog Scale (VAS) of 40 millimeters, received no pain-controlling medication, and had no other severe disease at its final stage were randomly assigned to two groups (n=52) through the four block method. One group received Duloxetine and the other received Gabapentin. The effectiveness was measured through primary effectiveness (VAS scale) and secondary effectiveness (Sleep Interference Score, and Clinical Global Impression of Change (CGIC)). Medication compliance was assessed by enumerating the number of patients who refused treatment because of side effects. The Fisher’s exact T-test and ANOVA were used for data analysis. This study was approved by the Ethics Committee of Jundishapur, University of Medical sciences Ahvaz, Iran, under reference number: IR.AJUMS.REC.1395.78. In addition, this study was registered and approved in the Iranian Registry of Clinical Trials (IRCT ID: IRCT20161023030455N2) (http://irct.ir/). Results: VAS, Sleep Interference Score, and CGIC were significantly improved (P<0.05) through time in both groups, [For GBP: VAS Baseline, =64±20.03, VAS week1, =55.32±18.76, VAS week4, =44.68±15.82, VAS week8, =39.43±14.32; For DLX: VAS Base-line, =62±21.18, VAS week1, =58.76±20.37, VAS week4, =45.84±16.21, VAS week8, =36.78±15.62] while a significant difference between the two groups was not observed (P<0.05). However, such significant improvements were not observed in the Duloxetine group at the end of the first week (P=674). Improvement in Sleep Interference Score and CGIC were similar to the results for the VAS scale. Side effects in the Duloxetine group (n=2) compared to the Gabapentin group (n=9) were significantly less (P<0.001). As a result, medication acceptance in the Duloxetine group (n=47) was significantly better than the Gabapentin (n=41) group (P<0.001). Conclusion: Both Duloxetine and Gabapentin are effective for the treatment of PDPP. On the one hand, Gabapentin shows the effect earlier while has more side effects. Conversely, Duloxetine has better medication compliance. Trial registration: The method of this study was approved by the Ethics Committee of Jundishapur University of Medical Sciences, Ahvaz, Iran, under reference number: IR.AJUMS.REC.1395.78. In addition, this study was registered and approved in the Iranian Registry of Clinical Trials (IRCT ID: IRCT20161023030455N2) (http://irct.ir/). Keywords: Duloxetine, Gabapentin, painful diabetic peripheral neuropathy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At present, among pharmacological options, pregabalin588–598 and duloxetine594,595,599,600 are oral agents that have received regulatory approval for the treatment of neuropathic pain associated with DPN by the FDA and are effective for DPN pain reduction when using patient-reported outcomes.547”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [596]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Üstün, Y. E. (2019) · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · Cited by 169,581
Boulton, A. J. M., Vinik, A. I., Arezzo, J. C., Bril, V., Feldman, E. L., Freeman, R., Malik, R. A., Maser, R. E., Sosenko, J. M., & Ziegler, D. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.956 · Cited by 1,859
Backonja, M. (1998) · JAMA · doi:10.1001/jama.280.21.1831 · Cited by 1,533 · cited 2×
“A large placebo-control study showed that Gabapentin is effective in the treatment of painful diabetic peripheral neuropathy.(1,15) A recent randomized, multi-center placebo-controlled study showed that Duloxetine was more effective than placebo in controlling PPP and it improved VAS mean score by 50% in 24 hrs.”
BackgroundYoung, M. J., Boulton, A. J. M., Macleod, A. F., Williams, D. R. R., & Sonksen, P. H. (1993) · Diabetologia · doi:10.1007/bf00400697 · Cited by 1,502 · cited 1×
“10 Since neuropathic symptoms intensify at night, sleep disorders happen and this not only affects the patient ’ s quality of life, but also worsens his/her diabetes.”
BackgroundAssociation of sleep time with diabetes mellitus and impaired glucose tolerance
Gottlieb, D. J., Punjabi, N. M., Newman, A. B., Resnick, H. E., Redline, S., Baldwin, C. M., & Nieto, F. J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.8.863 · Cited by 927 · cited 1×
“11 A mellitus diabetic patient who complains of foot or lower limb pain is normally diagnosed with painful diabetic peripheral neuropathy.”
BackgroundDuloxetine vs. placebo in patients with painful diabetic neuropathy
Goldstein, D. J., Lu, Y., Detke, M. J., Lee, T. C., & Iyengar, S. (2005) · Pain · doi:10.1016/j.pain.2005.03.029 · Cited by 858 · cited 1×
“…placebo-controlled study showed that Duloxetine was more effective than placebo in controlling PPP and it improved VAS mean score by 50% in 24 hrs. 26 The results of the above studies are in line with the results of this study and show that both medications are effective in treating pain of the…”
ResultThe Prevalence, Severity, and Impact of Painful Diabetic Peripheral Neuropathy in Type 2 Diabetes
Davies, M., Brophy, S., Williams, R., & Taylor, A. (2006) · Diabetes Care · doi:10.2337/dc05-2228 · Cited by 746
Bymaster, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00298-6 · Cited by 717
The spectrum of neuropathy in diabetes and impaired glucose tolerance
Sumner, C. J., Sheth, S., Griffin, J. W., Cornblath, D. R., & Polydefkis, M. (2003) · Neurology · doi:10.1212/wnl.60.1.108 · Cited by 708 · cited 1×
“14 The basis of treatment and control of all diabetic complications is glucose control.”
Background
Research works printed but not linked: 1
- [12]King SA. Diabetic peripheral neuropathic pain: effective management. Consultant. 2008; 48(11): 825.
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Antidepressants for pain management in adults with chronic pain: a network meta-analysis
Birkinshaw, H., Friedrich, C., Cole, P., Eccleston, C., Serfaty, M. A., Stewart, G. B., White, S. P., Moore, A., Phillippo, D., & Pincus, T. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014682.pub2 · Cited by 222
Pharmacological Management of Painful Peripheral Neuropathies: A Systematic Review
Liampas, A., Rekatsina, M., Vadalouca, A., Paladini, A., Varrassi, G., & Zis, P. (2020) · Pain and Therapy · doi:10.1007/s40122-020-00210-3 · Cited by 85
Prevention and Management Strategies for Diabetic Neuropathy
Smith, S., Normahani, P., Lane, T. R. A., Hohenschurz‐Schmidt, D., Oliver, N. S., & Davies, A. H. (2022) · Life · doi:10.3390/life12081185 · Cited by 99
The Treatment of Painful Diabetic Neuropathy
SLOAN, G. P., Alam, U., Selvarajah, D., & Tesfaye, S. H. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210707112413 · Cited by 71
Glutamatergic systems in neuropathic pain and emerging non-opioid therapies
Temmermand, R., Barrett, J. E., & Fontana, A. C. K. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106492 · Cited by 70
An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy
Qureshi, Z., Ali, M. N., & Khalid, M. (2022) · Journal of Diabetes Research · doi:10.1155/2022/9989272 · Cited by 44
“Comparative double blinded study was conducted with gabapentin and duloxetine which suggested that the former shows more side effects whereas the later shows more medication compliance [129].”
BackgroundPharmacotherapeutic Options for Managing Neuropathic Pain: A Systematic Review and Meta-Analysis
Stefano, G. D., Lionardo, A. D., Pietro, G. D., Cruccu, G., & Truini, A. (2021) · Pain Research and Management · doi:10.1155/2021/6656863 · Cited by 41
“In two RCTs, the effect of duloxetine 60mg and amitriptyline 10mg was compared to that of gabapentin 900mg [6, 8].”
BackgroundNeuromodulation Interventions for the Treatment of Painful Diabetic Neuropathy: a Systematic Review
D'Souza, R. S., Langford, B. J., Dombovy‐Johnson, M. L., & Abd-Elsayed, A. A. (2022) · Current Pain and Headache Reports · doi:10.1007/s11916-022-01035-9 · Cited by 39
“However, prior randomized clinical trials have highlighted that these pharmacologic agents may offer limited efficacy and are plagued with a high incidence of side effects [4, 5].”
BackgroundDiabetic neuropathy: Past, present, and future.
Aldave, J. E. Q., Durand‐Vásquez, M. D. C., Osorio, E. R. G., Suárez-Rojas, J., Roseboom, P. J., Alcalá‐Mendoza, R. M., Arroyo, J., Zavaleta‐Gutiérrez, F. E., Urteaga, L. A. C., & Concepción‐Zavaleta, M. J. (2023) · PubMed Central · doi:10.22088/cjim.14.2.153 · Cited by 47
“Gabapentin (149) Second-line Anti-convulsant GABA 900-3600 4-6”
Babiloni, A. H., Beetz, G., Bruneau, A., Martel, M. O., Cistulli, P. A., Nixdorf, D. R., Conway, J. M., & Lavigne, G. J. (2021) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2021.101459 · Cited by 33
A randomized control trial of duloxetine and gabapentin in painful diabetic neuropathy
Khasbage, S. U., Shukla, R. K. G., Sharma, P., & Singh, S. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13148 · Cited by 25
“The gabapentin group reported more adverse events, which may be because of higher than normal recommend dose (900 mg/day) used in the study.(20) Devi et al(11) evaluated clinical efficacy of gabapentin, duloxetine, and pregabalin in PDN.”
MethodNeuropharmacology of Neuropathic Pain: A Systematic Review
Mian, M. U., Afzal, M., Butt, A. A., Ijaz, M., Khalil, K., Abbasi, M., Fatima, M., Asif, M. F., Nadeem, S., Jha, S., et al. (2024) · Cureus · doi:10.7759/cureus.69028 · Cited by 25
“After one week, these medications should be discontinued, and only duloxetine should be used [21], considering that gabapentin works fast, and duloxetine works late but shows lesser side effects.”
BackgroundInfluentialJiang, L., Xiong, Y., & Cui, J. (2022) · Contrast Media & Molecular Imaging · doi:10.1155/2022/4084420 · Cited by 23
Sadegh, A. A., Gehr, N. L., & Finnerup, N. B. (2024) · PAIN Reports · doi:10.1097/pr9.0000000000001138 · Cited by 28
Ko, Y., Lee, C., Wu, C., & Huang, Y. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14576 · Cited by 23
The use of antineuropathic medications for the treatment of chronic pain
Urits, I., Li, N., Berardino, K., Artounian, K., Bandi, P., Jung, J. W., Kaye, R. J., Manchikanti, L., Kaye, A. M., Simopoulos, T. T., et al. (2020) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2020.08.007 · Cited by 23
Wu, Y., Guo, X., & Zhang, J. (2025) · Pain and Therapy · doi:10.1007/s40122-025-00771-1 · Cited by 15
Hassanzadeh, S., Bagheri, S., Ahmadi, S. M., Ahmadi, S. A., Moradishibany, I., Dolatkhah, H., & Reisi, S. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01486-0 · Cited by 13
“In previous investigations, the results of melatonin [14, 15], caffeine [16], capsaicin [17], vitamin B12 [18], alpha-lipoic acid [19], vitamin E [20], acupuncture [21], gabapentin and duloxetine [22, 23], pregabalin and gabapentin [24], gabapentin [25, 26], the topical combination of clonidine and pentoxifylline [27]…”
BackgroundDiabetic Neuropathy: a Critical, Narrative Review of Published Data from 2019
Nagpal, A., Leet, J., Egan, K. E., & Garza, R. (2021) · Current Pain and Headache Reports · doi:10.1007/s11916-020-00928-x · Cited by 11
Ahn, J., Shahriarirad, R., Kwon, K., Bejarano‐Pineda, L., Waryasz, G. R., & Ashkani‐Esfahani, S. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109001 · Cited by 9
Painful diabetic polyneuropathy: evidence-based diagnosis and treatment
Khramilin, V. N., & Давыдов, О. С. (2021) · Russian Journal of Pain · doi:10.17116/pain20211904144 · Cited by 10
Khodaie, S.-A., Nikkhah, H., Namiranian, N., Abotorabi, M., Askari, M., Khalilzadeh, S. H., Aghda, A. K., & Kamalinejad, M. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01338-2 · Cited by 10
Saxena, A. K., Thanikkal, N., Chilkoti, G. T., Gondode, P. G., Sharma, T., & Banerjee, B. D. (2024) · Pain Management · doi:10.1080/17581869.2024.2370758 · Cited by 8
Shah, I., Ahmad, W., Islam, M. F., Jan, B., Haq, E. U., Mahmood, J., Iqbal, N., & Shah, M. (2022) · Cureus · doi:10.7759/cureus.28683 · Cited by 8
“On the other hand, PGB is an anticonvulsant that reduces diabetic peripheral neuropathic pain via inhibition of pain sensors, increasing the pain threshold, and inhibiting the calcium ion channels in the postsynaptic dorsal root pain fibers [14].”
BackgroundPan, T., Ma, J., Li, Y., Wang, K., Jiang, C., Zhang, Y., Liu, J., Du, R., Zhang, W., Bian, F., et al. (2025) · Pain and Therapy · doi:10.1007/s40122-025-00745-3 · Cited by 7
“Although glycemic control is essential for managing all diabetes-related complications, the adoption of effective pain management strategies is equally vital for improving the overall health of patients with DPNP [23, 25].”
Redefining the Role of Analgesic Adjuvants in Pain Management: A Narrative Review
Nwosu, A. D. G., Chukwu, L. C., Onwuasoigwe, O., Nweze, S. O., & Nwadike, K. I. (2023) · Indian Journal of Pain · doi:10.4103/ijpn.ijpn_23_22 · Cited by 11
Nabi, B. N., Saberi, A., Eghbali, B. B., Hosseininezhad, M., Biazar, G., Malekabadi, A. A., & Mirmansouri, L. (2021) · Journal of Advances in Medical and Biomedical Research · doi:10.30699/jambs.29.136.286 · Cited by 8
“It has been known to have neuroprotective properties (2, 12).”
BackgroundValenzuela‐Fuenzalida, J. J., López-Chaparro, M., Barahona-Vásquez, M., Campos-Valdes, J., Gonzalez, J. C., Nova-Baeza, P., Orellana‐Donoso, M., Suazo-Santibáñez, A., Oyanedel-Amaro, G., & Gutiérrez‐Espinoza, H. (2024) · Pharmaceuticals · doi:10.3390/ph17070856 · Cited by 6
Usage of antiepileptic drugs in different diseases in Germany – A retrospective study
Scholten, J., Hamer, H. M., & Kostev, K. (2020) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2020.107210 · Cited by 6
Safety and efficacy of duloxetine versus gabapentin in painful diabetic polyneuropathy
Byndoor, Y., & Sagar, T. V. (2023) · IP International Journal of Comprehensive and Advanced Pharmacology · doi:10.18231/j.ijcaap.2022.042 · Cited by 5
Attar, A., Halabi, M. H., Barnawi, E. T., Sindi, G., Altayeb, A. A., Fadel, F. T., Alsubhi, L. H., Alsamiri, G. Y., & Alsabban, A. S. (2025) · British Journal of Pain · doi:10.1177/20494637251365690 · Cited by 5
“Notably, although multiple studies reported similar adverse events within the duloxetine group, 1,2,6 Ahmed et al. identi fi ed peripheral edema as one of the most common side effects associated with duloxetine use.”
Shi, Y., Chen, Y., & Zhao, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1750441 · Cited by 3
“They act through different mechanisms, pregabalin mainly targets speci fi c receptors on nerve cells ( a 2-d subunits of voltage-gated calcium channels), duloxetine increases the availability of certain neurotransmitters in the central nervous system (22, 23).”
Dash, L., Kumar, B., Anupriya, A., Reddy, V. B., Melkani, I., Pandey, N. K., Joshi, K., & Patel, D. (2022) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2022.00311 · Cited by 2
"Role of Different Pain Killers in Control of Diabetic Neuropathy Pain-A Review"
Iqbal, N. (2021) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2021.39.006234
“Duloxetine monotherapy was found to be an equally potent agent as gabapentin for the treatment of Diabetic Polyneuropathy pain, however with much better tolerability [31].”
BackgroundRahmawati, I. (2022) · Jurnal Farmasi Indonesia · doi:10.31001/jfi.v19i1.1186
MANIFESTAÇÕES NEUROLÓGICAS CAUSADAS PELA INFECÇÃO POR SARS-COV-2: UMA REVISÃO DE LITERATURA
Gasparoto, V. G., Ferreira, C. L. D. S., Talarico, A. L. D. S. C., Silqueira, B. G., Cazeloto, A. C. V., & Papassidero, P. C. (2022) · doi:10.22533/at.ed.70822240610
Faria, T. V. V., Agostinho, S. R., Lopes, P. D. A. C., Nose, A. L. Y., & Maciel, T. A. D. S. (2022) · doi:10.22533/at.ed.7082224069
Neto, J. F. D. A., de Lima, L. F. G., Neto, O. D. C. F., Dias, A. J. A., Lemos, N. B., Diniz, A. M. S., & Severo, L. (2022) · doi:10.22533/at.ed.7082224068
O VALOR SEMIÓTICO DO SINAL DE SOARES EM VIDEOLAPAROSCOPIA: SINAL DE PROBABILIDADE OU DE PRESUNÇÃO
Barbosa, C. D. A., da Cunha, A. J., Fernandes, M. M., Santiago, T. C., de Souza, F. A. M., da Cunha, D. H., Tannús, L. M. D. S., Guimarães, M. F., & de Oliveira, A. L. M. F. (2022) · doi:10.22533/at.ed.70822240611
A IMPORTÂNCIA DOS MÉTODOS NÃO FARMACOLÓGICOS NO TRATAMENTO DA DEPRESSÃO
Drillard, I. D. O., Zacarias, W. R., Siqueira, B. D. R., Cunha, C. A. P., Coelho, L. S. Z., Barbieri, V. X., da Costa, E. D. C., Duarte, M. E. D. C., & Júnior, H. S. D. F. (2022) · doi:10.22533/at.ed.7082224061
PANORAMA EPIDEMIOLÓGICO DOS INTERNADOS POR SEPTICEMIA NO BRASIL (2016-2020)
Francis, G. H. F., Júnior, P. R. H., Machado, N. D. O. F., Costa, V. E. N., Telhada, A. A. C. M., Esteves, G. S., Neto, R. M. B., Côrtes, J. V. D. R., Bastos, R. M., & Côrtes, P. P. D. R. (2022) · doi:10.22533/at.ed.7082224065
EFEITOS DA REABILITAÇÃO NA CAPACIDADE FUNCIONAL DE PACIENTES COM COVID-19
Corrêa, M. S. D. S., Moura, N. L. C., & Fernandes, G. A. (2022) · doi:10.22533/at.ed.7082224064
ATUAÇÃO DA FISIOTERAPIA ONCOLÓGICA NOS CUIDADOS PALIATIVOS EM CRIANÇAS COM OSTEOSSARCOMA
Mendonça, A. R. T., Figueiredo, D. T., da Silva, J. S., Júnior, W. C. C., Tavera, G. C., Neves, W. P., Amorim, J. D. D. O., Santana, M. D. A., Cardoso, A. C. D. A., Castelo, E. A. M., et al. (2022) · doi:10.22533/at.ed.7082224062
SUBTRATAMENTO DA DOR EM MULHERES: COMO OS PAPÉIS DE GÊNERO INFLUENCIAM ESSA DISPARIDADE?
Ribas, L. A., Silva, Y. L., de Menezes, M. D. M. C., Júnior, P. R. H., de Oliveira, J. B., Gomes, J. Y. H., Amorim, T. A., Montalvão, A. M., Oliveira, B. G., Pinheiro, M. T., et al. (2022) · doi:10.22533/at.ed.70822240620
Prathyusha Rani, T., Jillila, S. J., Vankudoth, S., Beeram, M. P. R., & sagar, S. V. (2022) · International Journal of Pharmaceutical Sciences and Nanotechnology · doi:10.37285/ijpsn.2022.15.5.7
Balasundaram, M. K., Kannauje, P. K., Dhaneria, S., & Singh, A. D. (2024) · Annals of Neurosciences · doi:10.1177/09727531241243126
“20 Another randomised, double-blind study assessed the efficacy and safety of duloxetine and gabapentin in diabetic peripheral neuropathy.”
Zhou, J., & Li, Y. H. (2025) · Neurology Asia · doi:10.54029/2025sca
Tong, S., Greenberg, J. R., Marini, C., Seixas, A. A., Doan, L., Osorio, R. S., & Thawani, S. P. (2025) · Current Sleep Medicine Reports · doi:10.1007/s40675-025-00332-0
“It can be assumed that patients will recover faster from the side effects of gabapentin if they are able to tolerate its side effects [21].”
刘, 妍. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.161100
Zerefos, I., Joshi, A., Namous, F., & Espiridion, E. D. (2026) · Journal of Family and Community Medicine · doi:10.4103/jfcm.jfcm_361_25
“[15] Broader meta‑analyses corroborate that each agent provides analgesic benefit, yet highlight the paucity of data on mood‑related endpoints.”
Лечение на болката при диабетна полиневропатия
Atanasova-Ivanova, K. A., Milanov, I. G., & Bogdanova, D. (2025) · Българска неврология · doi:10.67667/neu.v26i1.197
“Gabapentin постига по-бърз ефект, но има повече странични ефекти, докато duloxetine показва по-добър къмплайънс от страна на пациента (31).”
Agrawal, N., Sharma, A., Chandrashekar, A., Kazi, M. A. I., Karpman, M., Singh, S., & Muganlinskaya, N. F. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05807-7
Eritromelalgia secundaria a diabetes mellitus tipo 1 enpediatría, una presentación infrecuente
Franciulli, M. N., Silberkasten, M., Montaño, C. F. R., Martín, E. S., & Andrés, M. E. (2026) · Archivos Argentinos de Pediatria · doi:10.5546/aap.2026-11090
Kumar, A., Shrivastava, A., Kumar, V., Gupta, P., Barik, R. K., Dwivedi, A., Chaturvedi, P., Upadhayay, K., Dwivedi, S., & Gupta, J. K. (2026) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-026-00667-1
Reddy, S., Ahmed, S., & Chattopadhyay, M. (2026) · Medical Sciences · doi:10.3390/medsci14060649
Metadata
- Authors
- Majdinasab, N., Kaveyani, H., & Azizi, M.
- Affiliations
- Ahvaz Jundishapur University of Medical Sciences (IR)
- Corresponding author
- Kaveyani, Hossein
- ORCID
- Majdinasab, Nastaran
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2019-06
- Volume
- Volume 13
- Pages
- 1985-1992
- ISSN
- 1177-8881 (ISSN-L)
- PMC
- PMC6588725
- OpenAlex
- W2952712394
- Cited by
- 54
- References
- 30
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 19 · 2021: 8 · 2020: 4
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Drug Design Development and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Ahvaz Jundishapur University of Medical Sciences
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Keywords
- diabetic neuropathic pain, duloxetine, gabapentin, sleep interference, medication adherence, adverse effects, antidepressants, antiepileptic drugs, pain intensity, Clinical Global Impression of Change, visual analogue scale, treatment effectiveness comparison, sleep quality, quality of life, diabetes complications
- MeSH terms
- Duloxetine Hydrochloride, Gabapentin, Administration, Oral, Adolescent, Adult, Aged, Analgesics, Diabetic Neuropathies, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuralgia, Prospective Studies, Young Adult, Pain Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
